erlotinib hydrochloride has been researched along with ag 1879 in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (ag 1879) | Trials (ag 1879) | Recent Studies (post-2010) (ag 1879) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 575 | 0 | 215 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | ag 1879 (IC50) |
|---|---|---|---|
| Chain A, Lck Kinase | Homo sapiens (human) | 0.02 | |
| Chain A, Tyrosine-protein kinase Lyn | Mus musculus (house mouse) | 0.009 | |
| Chain A, Tyrosine-protein kinase Lyn | Mus musculus (house mouse) | 0.009 | |
| Receptor-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | 0.019 | |
| Proto-oncogene tyrosine-protein kinase Src | Gallus gallus (chicken) | 0.036 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.48 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.004 | |
| Proto-oncogene tyrosine-protein kinase LCK | Mus musculus (house mouse) | 0.031 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 0.0052 | |
| Tyrosine-protein kinase Lyn | Homo sapiens (human) | 0.0005 | |
| Tyrosine-protein kinase HCK | Homo sapiens (human) | 0.005 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 1.1814 | |
| Tyrosine-protein kinase CSK | Homo sapiens (human) | 0.5 | |
| Casein kinase I isoform delta | Homo sapiens (human) | 0.041 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 4.23 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adès, L; Boehrer, S; Bouteloup, C; de Botton, S; Fenaux, P; Galluzzi, L; Gardin, C; Harper, F; Kroemer, G; Lainey, E; Pierron, G; Sébert, M; Tailler, M; Thépot, S | 1 |
1 other study(ies) available for erlotinib hydrochloride and ag 1879
| Article | Year |
|---|---|
Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biomarkers, Tumor; Enzyme Activation; Erlotinib Hydrochloride; Flow Cytometry; G1 Phase Cell Cycle Checkpoints; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Microscopy, Electron; Microscopy, Fluorescence; Microtubule-Associated Proteins; Phosphorylation; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; src-Family Kinases; Stilbenes; TOR Serine-Threonine Kinases | 2011 |